OUR HISTORY
AfriqVax was incorporated in 2024 in response to the African Union ambitious goal, to have manufacturers based on the continent develop, produce, and supply more than 60% of the vaccine doses required on the continent by 2040. Also, Nigeria being the most populous country in Africa exploring local manufacture of some of the routine vaccines as a sustainable exit strategy from Global Alliance for Vaccination and Immunization (GAVI) support.
OUR STRATEGY
Our Strategy is to focus on the following key areas:
1. Multi Product Fill and Finish Vaccine Manufacturing
2. Drug Substance Vaccine Manufacturing
3. Manufacturing of other biopharmaceuticals viz: Monoclonal Antibodies (MABs), Blood Plasma, Gene therapy, Biosimilars
4. Research and Development.
OUR PEOPLE
- Lekan Asuni
- Executive experience and set-up of pharmaceutical companies (GSK, Colexa etc)
- Extensive knowledge of the Africa Healthcare market.
- Dr Donald Gerson
- Executive experience and set-up of bio-manufacturing companies in CDMO and vaccine space (e.g., Celltrion, Wyeth, SaudiVax)
- Cooperation with Nobel Prize Winner for Medicine
- Total of 95 publications, 8 patents materials and GMP facilities
- Jonas Elliot Gerson
- Executive experience and set-up of bio-manufacturing companies in CDMO and vaccine (e.g.,Pnuvax, SaudiVax)
- Engineer Henry Akintade Ade
- Extensive project management experience in innovative Process and Industrial engineering industry
- Prior roles in advisory and consulting in advanced materials and GMP facilities.